Evergreening
Based on Wikipedia: Evergreening
In 1935, the federal government drew red lines around Black neighborhoods on city maps and declared them unfit for investment. The practice was called redlining, and its effects persist ninety years later. Decades ago, a different kind of line was drawn in the complex architecture of pharmaceutical law, not to exclude a neighborhood from capital, but to exclude generic competitors from a market. This is the strategy known as "evergreening." It is a legal, business, and technological maneuver designed to extend the lifetime of patents that are about to expire, allowing producers—most often pharmaceutical giants—to retain monopoly revenues for years longer than the law intended. At its core, it is a mechanism where innovation is not driven by the need to cure disease, but by the imperative to delay competition.
Robin Feldman, a law professor at UC Law SF and one of the world's leading researchers on intellectual property, defines this practice with surgical precision: evergreening is "artificially extending the life of a patent or other exclusivity by obtaining additional protections to extend the monopoly period." It is a game played in the gray areas of the law, where the letter of the statute is followed while its spirit is systematically dismantled. In the pharmaceutical industry, the stakes are not merely financial; they are existential for patients waiting for affordable medication. When manufacturers of a specific drug employ these tactics, their goal is singular: to restrict or prevent competition from generic equivalents that would slash prices and make life-saving treatments accessible to the masses.
The scale of this phenomenon in the United States is staggering. In a landmark study of the prescription drug market, Feldman discovered that 78% of new patents associated with prescription drugs were not for novel cures, but for existing drugs already on the market. These are not breakthroughs; they are refinements designed to reset the clock. The financial impact is corrosive. In 2002, the US Federal Trade Commission (FTC) found that generic drug manufacturers intending to bring new drugs to market were subjected to legal action by the original patent holder up to 75% of the time. These lawsuits act as a brake on competition, resulting in increased drug costs for consumers and insurers alike. The system was not designed to be this way; it was hijacked by those who realized that the cost of litigation was far lower than the loss of monopoly profits.
One of the most insidious tactics employed is known as "product hopping" or "product switching." This anti-competitive practice involves patenting a minor variation on an original product, thereby creating a new revenue stream and delaying the entry of generics. The logic is predatory: if a generic company manages to produce a version of the drug that matches the original formulation just as the first patent expires, the brand-name manufacturer "hops" the market. They introduce a slightly modified version—perhaps a different chemical mixture or a new delivery mechanism—and aggressively market it while simultaneously withdrawing or ceasing production of the old version.
This forces doctors and patients to switch to the new, still-patented formulation. Because generic substitution laws often require pharmacists to dispense the specific version on file, and because the "old" version is no longer available, the generic competitor finds itself without a market. The patient cannot get the cheap alternative because the product it copies has been effectively pulled from the shelf. This prevents competition and harms consumer welfare in ways that are often invisible to the naked eye. The public does not see a price hike; they simply see their doctor writing a new prescription for a "new" drug, unaware that they are paying double or triple what they would have if the generic had been allowed to enter.
The types of product hops are varied and technically sophisticated. They include changing the physical form of the drug from a capsule to a tablet, making minor chemical adjustments such as adding different chemical groups (creating a "me-too" drug), or switching to a different enantiomeric mixture in what is known as a "chiral switch." Manufacturers may also switch from short-acting to long-acting formulations or introduce new inactive ingredients. In other cases, they combine drugs that were previously sold separately into a single pill.
Distinguishing these anti-competitive hops from genuine medical improvements is the central challenge for regulators and courts. A change in drug form is not inherently bad; if a new version offers an easier route of administration that leads to meaningful benefits for patients, it represents progress. However, a meaningful improvement may still be considered a product hop if it was introduced as part of an anticompetitive strategy. The intent matters. If the primary driver is to block generics rather than help patients, the innovation becomes a weapon.
The consequences of this strategy are measured in billions of dollars and, more importantly, in human access to care. In one notable case involving the multiple sclerosis drug glatiramer acetate (Copaxone), product hopping led to a cost burden on consumers ranging from $4.3 billion to $6.5 billion over just two and a half years. The new patent was eventually invalidated by the courts, but by then, millions had already paid inflated prices. Another stark example is the Alzheimer's drug memantine (Namenda). The manufacturer engaged in a product hop that forced a transition to a once-daily formulation while threatening to discontinue the twice-daily version that generics could have copied. The impact was not just financial; it disrupted care for vulnerable elderly patients who were being shuffled between formulations in a chess match they did not understand and could not afford.
Withholding the release of new product versions has also emerged as a tactic. Firms may sit on a superior formulation, waiting until their current version is about to face generic competition before releasing the new one. This maximizes profit over patient benefit, ensuring that the monopoly extends across multiple product generations. Litigation against Gilead Sciences addressed this issue of product versioning directly, highlighting the profound problems inherent in compensating patients who were impacted by these tactics. Yet, compensation often comes too late. The damage is done when a family loses savings or foregoes treatment because the cost was artificially inflated.
The legal analysis of product hopping under antitrust laws is notoriously complex, largely due to the unique nature of healthcare markets. As of 2015, the distinction between encouraging innovation and preventing monopolization remained unclear in many jurisdictions. Legal scholars have proposed specific criteria to define a product hop: first, modifying the product specifically to prevent substitution by a generic drug; and second, actively encouraging prescriptions of the new version over the original. The switch can be encouraged through aggressive marketing or forced by discontinuing the old version entirely.
Another critical factor in this analysis is economic soundness. Would the company have made the switch if it were not for the threat of generics? If a product hop makes no sense economically unless it blocks competition, it is a strong indicator of anti-competitive intent. The courts are left to weigh these factors, often navigating a minefield where the line between legitimate business strategy and illegal monopolization is blurred by layers of patent law and regulatory procedure.
The process of evergreening extends beyond domestic markets; it involves specific aspects of international trade law and treaty obligations. One such mechanism is "linkage evergreening." This occurs when pharmaceutical safety, quality, and efficacy regulators are required to "link" their normal evaluation of a drug with an assessment of whether an impending generic product might infringe on an existing patent. In this system, the health regulator cannot approve a generic drug until all relevant patents have expired or been litigated. It effectively transforms the regulatory agency into a private enforcer for patent holders.
The inclusion of linkage provisions in international trade agreements has sparked intense debate and diplomatic friction. A prime example occurred with the Australia-United States Free Trade Agreement (AUSFTA). Article 17.10.4 of the agreement required that member nations implement linkage obligations as a condition for the treaty to come into force. To comply, amendments were made to Australia's Therapeutic Goods Act 1989. A new section, 26B, was inserted, requiring applicants for marketing approval to certify that their product would not infringe on valid patent claims or that the patent holder had been notified of the application.
However, the Australian government, recognizing the threat this posed to public health and affordable medicine, moved quickly to counteract the most damaging potential effects. They passed anti-evergreening amendments in Sections 26C and 26D of the Therapeutic Goods Act. These provisions were designed specifically to prevent patent holders from manipulating the court system to lengthen the term of their patents and delay the entry of generic pharmaceuticals into the market. They stand as a strong statement of Australia's legitimate expectations: that citizens have a right to freedom from pharmaceutical price rises caused by artificial monopoly extensions.
The tension between international trade commitments and domestic public health needs was laid bare in an exchange of letters in November 2004. The Chief Australian negotiator stated unequivocally, "We are not importing the Hatch-Waxman legislation into Australian law as a result of the free trade agreement...[Article 17.10.4] will not extend the time of the marketing approval process, and it does not add or provide any additional rights to the patent holders in that process." The negotiator assured that no injunction could be applied under this article and that the legislation would clearly meet commitments without harming competition.
The United States, however, signaled its disapproval of Australia's implementation with sharp diplomatic pressure. In an exchange between the Australian Minister for Trade and the US Trade Representative (USTR), the USTR stated: "If Australia's law is not sufficient to prevent the marketing of a product... where the produce or use is covered by a patent, Australia will have acted inconsistently with the Agreement." The letter warned that the US would be monitoring the matter closely and reserved all rights and remedies.
The US expressed specific concern about the amendments to Sections 26B(1)(a), 26C, and 26D of the Therapeutic Goods Act. They argued that under these amendments, pharmaceutical patent owners risked incurring significant penalties when seeking to enforce their rights. The USTR claimed these provisions imposed a "potentially significant, unjustifiable, and discriminatory burden on the enjoyment of patent rights," specifically targeting owners of pharmaceutical patents. "I urge the Australian Government to review this matter," the letter read, invoking Australia's international legal obligations as a lever for change.
The capacity of the US to make such threats is arguably facilitated by the linkage of Article 17.10.4 to a non-violation nullification of benefits provision in the trade agreement. This creates a scenario where a nation can be penalized under the treaty even if it has not technically violated the text, simply because its laws fail to provide the level of protection the US desires for its corporations. The stakes are high: trade sanctions or loss of market access for other industries could hang over a country that prioritizes generic drug access over patent holder profits.
Similar battles have been fought across the border in Canada. In 1993, under regulations induced by the North American Free Trade Agreement (NAFTA), known as the Notice of Compliance (NOC) regulations, Health Canada was prevented from issuing an authorization for market entry until all relevant patents on a brand-name product had been proven to have expired. This created a procedural bottleneck that favored patent holders. When a Canadian generic company, such as Apotex, submitted its application for approval, it also sent a Notice of Allegation (NOA) to the patent holder claiming no infringement occurred.
The patent holder then had 45 days to initiate an application in the Federal Court of Canada, seeking an order to prohibit the relevant Minister from issuing the approval. This legal stay effectively froze the generic market entry for months or even years while litigation dragged on. The system was designed to give patent holders a chance to sue before competition could enter, but it often resulted in delays that had nothing to do with the validity of the patents and everything to do with the cost of defense for smaller generic firms.
The human cost of these legal machinations is often obscured by the jargon of "patent term extensions," "regulatory linkage," and "product hopping." Yet, behind every delayed generic approval is a patient who cannot afford their medication. It is a parent choosing between insulin and groceries; it is an elderly person rationing heart medication to stretch their savings. The $4.3 billion paid for Copaxone was not just money lost by insurance companies; it was resources that could have been used for research, for expanding access to other treatments, or simply returned to families struggling to make ends meet.
The argument from the pharmaceutical industry is one of innovation. They claim that without the ability to extend patents through these various mechanisms, they would not have the financial incentive to develop new drugs. The logic follows that the monopoly profits are necessary to recoup the massive costs of research and development. However, studies like Feldman's suggest that a significant portion of this "innovation" is actually defensive. If 78% of new patents are for existing drugs, then the system is not primarily driving the discovery of cures for diseases we do not yet understand; it is driving the refinement of what we already have to keep the revenue stream intact.
There is a fundamental asymmetry in this relationship. The patent holder has vast resources to litigate, delay, and lobby. The generic manufacturer, often smaller and operating on thinner margins, must navigate a labyrinth of legal traps just to offer an equivalent product at a fraction of the cost. And the patient, caught in the middle, bears the burden of the system's inefficiencies. They are asked to trust that the "new" version is better, unaware that it may be no more effective than the old one, only cheaper for someone else to produce.
The distinction between encouraging innovation and preventing monopolization remains one of the most contentious issues in modern healthcare policy. As long as the law allows for these artificial extensions, companies will find ways to exploit them. The courts are left with the impossible task of determining what constitutes a "genuine" improvement versus a "strategic" hop. But perhaps the question should not be about parsing the differences between forms and formulations. Perhaps the question is whether a system that prioritizes the revenue streams of corporations over the immediate health needs of its citizens can ever be truly just.
The examples from Australia, Canada, and the United States show that this is not merely a technical debate for lawyers. It is a clash of values. On one side stands the global trade regime, which seeks to protect intellectual property as a commodity with universal rights. On the other stands national sovereignty and public health policy, which asserts that access to medicine is a right that cannot be held hostage by patent litigation. The amendments in Australia's Therapeutic Goods Act were a bold assertion of this second view, a declaration that the nation would not import a system that allowed its citizens to be priced out of their own healthcare.
As we look toward the future, the pressure to reform these systems will only grow. With drug prices rising globally and trust in the pharmaceutical industry eroding, the public is becoming more aware of the tactics used to delay generics. The "product hop" is no longer a secret maneuver; it is a recognized strategy that has been documented, analyzed, and criticized. The challenge for policymakers is to create frameworks that reward true innovation while closing the loopholes that allow for artificial monopoly extensions.
The story of evergreening is not just about patents; it is about power. It is about who gets to decide what a life-saving drug costs and who gets to decide when a generic competitor can enter the market. Until the balance shifts away from protecting monopolies and toward ensuring access, the cycle will continue. New patents will be filed for old drugs, minor variations will be marketed as breakthroughs, and millions of people will pay more than they should for medicine that has already proven its worth. The lines drawn in these legal documents are invisible to the patient, but their effects are felt in the wallet, in the pharmacy counter, and ultimately, in the health of the nation.
The fight against evergreening is a fight for the integrity of the patent system itself. If patents become tools solely for extending monopolies rather than rewarding genuine invention, they lose their moral and legal foundation. The examples of Copaxone and Namenda serve as cautionary tales. They show us what happens when the law is manipulated to the point where it harms the very people it was meant to protect. The path forward requires a re-evaluation of our priorities, a willingness to prioritize human welfare over corporate profit, and a commitment to ensuring that the benefits of medical science are shared by all, not hoarded by the few.
In the end, the measure of a healthcare system is not how many patents it grants or how much revenue its pharmaceutical companies generate. It is measured in the lives saved, the pain alleviated, and the dignity afforded to those who need care most. Evergreening stands as a barrier to that ideal, a complex web of legal strategies designed to keep costs high and competition low. Breaking that web requires more than just new laws; it requires a shift in perspective, recognizing that the right to health is not something that can be patented, extended, or sold for an extra few years of profit. It is a right that demands immediate action, unencumbered by the artificial delays of evergreening.